Parties d'ouvrages collectifs (5)
  1. 1. Depondt, C. (2019). Familial Focal Epilepsy with Variable Foci. In The Causes of Epilepsy: Common and Uncommon Causes in Adults and Children (2 ed., pp. 171-174). Cambridge University Press.
  2. 2. Depondt, C. (2009). Pharmacogenetics in Neurological Diseases. In M. Ritsner (Ed.), Neuropsychiatric Biomarkers, Endophenotypes, and Genes. Willey Sciences.
  3. 3. Depondt, C. (2008). Pharmacogenomics applications in epilepsy. In N. Cohen (Ed.), Pharmacogenomics and Personalized Medicine. Humana Press.
  4. 4. Depondt, C. (2008). Epilepsies due to monogenic disorders of metabolism. In S. Shorvon & T. Pedley (Eds.), The Epilepsies. Elsevier.(Blue Books of Neurology).
  5. 5. Pandolfo, M., & Depondt, C. (2007). Friedreich's Ataxia and Related DNA Loss-of-Function Disorders. In Molecular Neurology (pp. 277-294). Elsevier Inc. doi:10.1016/B978-012369509-3.50020-2
    6.   Articles dans des revues avec comité de lecture (110)
  6. 1. Demidov, G., Yaldiz, B., Garcia-Pelaez, J., de Boer, E., Schuermans, N., Van de Vondel, L., Paramonov, I., Johansson, L. F., Musacchia, F., Benetti, E., Bullich, G., Sablauskas, K., Beltran, S., Gilissen, C., Hoischen, A., Solve-RD Consortium,, Duerinckx, S., Ossowski, S., de Voer, R., Lohmann, K., Oliveira, C., Topf, A., Vissers, L. E. L. M. L., Laurie, S., Salmon, K., & Depondt, C. (2024). Comprehensive reanalysis for CNVs in ES data from unsolved rare disease cases results in new diagnoses. NPJ genomic medicine, 9(1), 49. doi:10.1038/s41525-024-00436-6
  7. 2. Costello, D., Matthews, E., Aurangzeb, S., Doran, E., Stack, J., Wesselingh, R., Dugan, P., Choi, H., Depondt, C., Devinsky, O. I., Doherty, C. P., Kwan, P., Monif, M., O'Brien, T. J., Sen, A., & Gaspard, N. (2024). Clinical outcomes among initial survivors of cryptogenic new-onset refractory status epilepsy (NORSE). Epilepsia. doi:10.1111/epi.17950
  8. 3. Boothman, I., Clayton, L. M. S., McCormack, M., Driscoll, A. M., Stevelink, R., Moloney, P., Krause, R., Kunz, W. W., Diehl, S., O'Brien, T., Sills, G., de Haan, G. J., Zara, F., Koeleman, B., Depondt, C., Marson, A. G., Stefansson, H., Stefansson, K., Craig, J., Johnson, M. R., Striano, P., Lerche, H., Furney, S., Delanty, N., Consortium EpiPGX,, Sisodiya, S. M., & Cavalleri, G. L. (2023). Testing for pharmacogenomic predictors of ppRNFL thinning in individuals exposed to vigabatrin. Frontiers in Neuroscience, 17, 1156362. doi:10.3389/fnins.2023.1156362
  9. 4. Tatillo, C., Legros, B., Depondt, C., Rikir, E., Naeije, G., Jodaitis, L., Ligot, N., & Gaspard, N. (2023). Prognostic value of early electrographic biomarkers of epileptogenesis in high-risk ischaemic stroke patients. European journal of neurology. doi:10.1111/ene.16074
  10. 5. ILAE, C. O. C. E., Depondt, C., et al. (2023). GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture. Nature genetics.
  11. 6. Montanucci, L., Depondt, C., Epi25 Collaborative,, et al. (2023). Genome-wide identification and phenotypic characterization of seizure-associated copy number variations in 741,075 individuals. Nature communications.
  12. 7. Feys, O., Goldman, S., Lolli, V., Depondt, C., Legros, B., Gaspard, N., Schuind, S., De Tiege, X., & Rikir, E. (2023). Diagnostic and therapeutic approaches in refractory insular epilepsy. Epilepsia. doi:10.1111/epi.17571
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 Suivant >>